Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, van Diessen JNA, Sonke JJ, de Ruysscher D. Cooke SA, et al. Among authors: dieleman emt. Radiother Oncol. 2024 Apr 24;196:110312. doi: 10.1016/j.radonc.2024.110312. Online ahead of print. Radiother Oncol. 2024. PMID: 38663582
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Walraven I, et al. Radiother Oncol. 2016 Mar;118(3):442-6. doi: 10.1016/j.radonc.2016.02.011. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900091 Clinical Trial.
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J. van Diessen J, et al. Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13. Radiother Oncol. 2019. PMID: 30327236 Clinical Trial.
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
Cooke SA, de Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, Lewensohn R, van Diessen JNA, Sikorska K, Lalezari F, Vogel W, van Elmpt W, Damen EMF, Sonke JJ, Belderbos JSA. Cooke SA, et al. Among authors: dieleman emt. Radiother Oncol. 2023 Apr;181:109492. doi: 10.1016/j.radonc.2023.109492. Epub 2023 Jan 24. Radiother Oncol. 2023. PMID: 36706958 Clinical Trial.
Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating.
van den Heuvel MM, Uyterlinde W, Vincent AD, de Jong J, Aerts J, Koppe F, Knegjens J, Codrington H, Kunst PW, Dieleman E, Verheij M, Belderbos J. van den Heuvel MM, et al. Radiother Oncol. 2014 Jan;110(1):126-31. doi: 10.1016/j.radonc.2013.10.009. Epub 2013 Nov 11. Radiother Oncol. 2014. PMID: 24225233 Clinical Trial.
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, Dieleman EMT, Jaspers JPM, Van Meerbeeck JP, Ubbels F, Kwint MH, Kuenen MA, Deprez S, De Ruiter MB, Boogerd W, Sikorska K, Van Tinteren H, Schagen SB. Belderbos JSA, et al. Among authors: dieleman emt. J Thorac Oncol. 2021 May;16(5):840-849. doi: 10.1016/j.jtho.2020.12.024. Epub 2021 Feb 2. J Thorac Oncol. 2021. PMID: 33545387 Free article. Clinical Trial.
The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E, van der Woude L, van Os R, van Bockel L, Coremans I, van Es C, De Jaeger K, Knol HP, Kolff W, Koppe F, Pomp J, Reymen B, Schinagl D, Spoelstra F, Tissing-Tan C, van der Voort van Zyp N, van der Wel A, Wijsman R, Dielwart M, Wiegman E, Damhuis R, Belderbos J. Dieleman E, et al. Clin Lung Cancer. 2023 Mar;24(2):130-136. doi: 10.1016/j.cllc.2022.11.008. Epub 2022 Nov 25. Clin Lung Cancer. 2023. PMID: 36572596 Free article.
Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens Y, Dieleman EMT, Jaspers JPM, Van Meerbeeck JP, Ubbels F, Kwint M, Kuenen M, Deprez S, De Ruiter MB, Boogerd W, Sikorska K, Van Tinteren H, Schagen SB. Belderbos JSA, et al. Among authors: dieleman emt. J Thorac Oncol. 2021 Jun;16(6):e42-e45. doi: 10.1016/j.jtho.2021.03.015. J Thorac Oncol. 2021. PMID: 34034890 Free article. No abstract available.
Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, Dieleman EMT, Jaspers JPM, Van Meerbeeck JP, Ubbels F, Kwint MH, Kuenen MA, Deprez S, De Ruiter MB, Boogerd W, Sikorska K, Van Tinteren H, Schagen SB. Belderbos JSA, et al. Among authors: dieleman emt. J Thorac Oncol. 2021 Aug;16(8):e63-e65. doi: 10.1016/j.jtho.2021.06.010. J Thorac Oncol. 2021. PMID: 34304858 Free article. No abstract available.
26 results